Protocol |
Title |
Status |
Contact |
104019 |
Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer |
OPEN TO ACCRUAL |
|
103792 |
A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (M18-868) |
OPEN TO ACCRUAL |
|
103952 |
Phase III Randomized Trial of Immunotherapy with or without Consolidative Radiotherapy for Oligometastatic Head and Neck Squamous Cell Carcinoma |
OPEN TO ACCRUAL |
|
103945 |
A Phase 2, Randomized Study to Evaluate the Safety, Efficacy and Optimal dose of ABBV-400 in Combination with Fluorouracil (5-FU), Folinic Acid and Bevacizumab in Previously Treated Subjects with Unresectable Metastatic Colorectal Cancer (mCRC) |
OPEN TO ACCRUAL |
|
103849 |
Feasibility Study- ReVeal FGS 475 System for Bevonescein-Assisted Intra-Operative Visualization of Nerves in Head and Neck Surgery |
OPEN TO ACCRUAL |
|
103819 |
A Phase III, Single Arm Study to Evaluate the Efficacy and Safety of ONCOFID P B (paclitaxel hyaluronic acid conjugate) Administered Intravesically to Patients with BCG unresponsive Carcinoma in Situ of the Bladder with or without Ta T1 Papillary Disease |
OPEN TO ACCRUAL |
|
103669 |
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA Positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer |
OPEN TO ACCRUAL |
|
103785 |
Multicenter, Open-Label, Phase 2 Study of Carboplatin Plus Mirvetuximab Soravtansine Followed by Mirvetuximab Soravtansine Continuation in Folate Receptor-Alpha Positive, Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Following 1 Prior Line of Platinum-Based Chemotherapy |
OPEN TO ACCRUAL |
|
103080 |
INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature Driven Analysis |
OPEN TO ACCRUAL |
|
103759 |
A Phase III, Multicenter, Open label Study of Ribociclib vs. Palbociclib in Patients With Advanced Hormone Receptor positive/HER2 negative/HER2 Enriched Breast Cancer HARMONIA Trial |
OPEN TO ACCRUAL |
|
103727 |
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma |
OPEN TO ACCRUAL |
|
103351 |
A Phase 1b Dose Escalation Study Of Metabolically Fit Cd19 Chimeric Antigen Receptor (Car) T Cells With Cd34 Selection Markers In Adult Patients With Relapsed Or Refractory Cd19 B Cell Non Hodgkin Lymphoma And Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
OPEN TO ACCRUAL |
|
103717 |
A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor |
OPEN TO ACCRUAL |
|
103253 |
Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma |
OPEN TO ACCRUAL |
|
103810 |
A Phase 1 Multicenter Dose Escalation and Dose Expansion Study of Antibody Drug Conjugate MYTX 011 in Subjects with Non Small Cell Lung Cancer |
OPEN TO ACCRUAL |
|
103416 |
Multicenter Phase 3 Pivotal Study to Evaluate the Safety and Efficacy of TOOKAD (padeliporfin) Vascular Targeted Photodynamic Therapy in the Treatment of Low Grade Upper Tract Urothelial Cancer |
OPEN TO ACCRUAL |
|
103839 |
A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined with Pemetrexed and Carboplatin in Patients with EGFRmutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment
(HARMONi) |
OPEN TO ACCRUAL |
|
103707 |
A Phase 1 Study of the SHP2 Inhibitor BBP 398 (formerly known as IACS 15509) in Combination with the Programmed Death Receptor 1 Blocking Antibody Nivolumab in Patients with Advanced Non Small Cell Lung Cancer with a KRAS Mutation |
OPEN TO ACCRUAL |
|
103725 |
Feasibility Trial of Preoperative 5 Day Hypofractionated Radiotherapy for Primary Soft Tissue Sarcoma |
OPEN TO ACCRUAL |
|
103896 |
A Phase III Randomized Trial of Radiotherapy Optimization for Low Risk HER2 Positive Breast Cancer\" (HERO) |
OPEN TO ACCRUAL |
|